Understanding how MEF2D affects acute myeloid leukemia
MEF2D-Mediated Transcriptional Control of Acute Myeloid Leukemia
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-10992599
This study is looking at how a protein called MEF2D affects the growth of acute myeloid leukemia (AML) cells with certain genetic changes, hoping to find new ways to treat this tough type of leukemia and help patients feel better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-10992599 on ClinicalTrials.gov |
What this research studies
This research investigates the role of MEF2D, a transcription factor, in the development and progression of acute myeloid leukemia (AML) with specific genetic rearrangements. By examining how MEF2D influences the behavior of leukemia cells, the study aims to identify new therapeutic targets that could improve treatment outcomes. The researchers will utilize various laboratory techniques to manipulate MEF2D levels and observe the resulting effects on leukemia cell differentiation and survival. This approach seeks to uncover genetic vulnerabilities that could lead to more effective therapies for patients with this aggressive form of leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with MLL gene rearrangements.
Not a fit: Patients with other types of leukemia or those without MLL gene rearrangements may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve survival rates for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results in targeting transcription factors in leukemia, suggesting that this approach may yield significant advancements.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LU, RUI — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: LU, RUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.